Cautious Outlook on Johnson & Johnson Amid Currency and Legal Challenges
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.
Johnson & Johnson price target lowered to $160 from $177 at Bernstein
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
STAT2d
Johnson & Johnson says its lung cancer drug significantly extended survival
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
JNJ has an attractive 3.41% dividend yield comparable to the yield on long-term bonds. Given the lack of price movement and ...
Johnson & Johnson stock outperforms competitors on strong trading day
Johnson & Johnson closed $22.62 below its 52-week high ($168.85), which the company achieved on September 4th.